Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

被引:11
|
作者
Miyazaki, Katsuki [1 ,2 ]
Morine, Yuji [2 ]
Xu, Caiming [1 ]
Nakasu, Chiharu [2 ]
Wada, Yuma [2 ]
Teraoku, Hiroki [2 ]
Yamada, Shinichiro [2 ]
Saito, Yu [2 ]
Ikemoto, Tetsuya [2 ]
Shimada, Mitsuo [2 ]
Goel, Ajay [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Diagnost & Expt Therapeut, Duarte, CA 91010 USA
[2] Tokushima Univ, Dept Surg, Tokushima 7791510, Japan
关键词
Lenvatinib; Curcumin; EGFR; hepatocellular carcinoma; PI3K-AKT; resistance; ATEZOLIZUMAB PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; NON-INFERIORITY; SORAFENIB; EFFICACY; CANCER; SAFETY;
D O I
10.3390/cells12040612
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] In vitro effect of curcumin-mediated antimicrobial photodynamic therapy on fibroblasts: viability and cell signaling for apoptosis
    Chaves Lamarque, Giuliana Campos
    Mendez, Daniela Alejandra Cusicanqui
    Matos, Adriana Arruda
    Dionisio, Thiago Jose
    Machado, Maria Aparecida Andrade Moreira
    Magalhaes, Ana Carolina
    Oliveira, Rodrigo Cardoso
    Cruvinel, Thiago
    LASERS IN MEDICAL SCIENCE, 2021, 36 (06) : 1169 - 1175
  • [42] Role of TGF-β signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells
    Raktima Datta
    Sunil K. Halder
    Binhao Zhang
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 563 - 572
  • [43] Erythropoietin signaling in cervical carcinoma: A pathway of hypoxia mediated treatment resistance
    Acs, G
    Zhang, PJ
    Mohyeldin, A
    Liu, S
    Lu, H
    McBroom, J
    Verma, A
    MODERN PATHOLOGY, 2003, 16 (01) : 178A - 178A
  • [44] In vitro effect of curcumin-mediated antimicrobial photodynamic therapy on fibroblasts: viability and cell signaling for apoptosis
    Giuliana Campos Chaves Lamarque
    Daniela Alejandra Cusicanqui Méndez
    Adriana Arruda Matos
    Thiago José Dionísio
    Maria Aparecida Andrade Moreira Machado
    Ana Carolina Magalhães
    Rodrigo Cardoso Oliveira
    Thiago Cruvinel
    Lasers in Medical Science, 2021, 36 : 1169 - 1175
  • [45] GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma
    Xie, Peiyi
    Wu, Mengyuan
    Wang, Hui
    Zhang, Bo
    Zhang, Zihao
    Yan, Jiuliang
    Yu, Mincheng
    Yu, Qiang
    Zhao, Yufei
    Huang, Da
    Xu, Min
    Xu, Wenxin
    Li, Hui
    Xu, Yongfeng
    Xiao, Yongsheng
    Guo, Lei
    ONCOGENE, 2024, : 3108 - 3120
  • [46] EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
    Yalei Yin
    Mingju Sun
    Xi Zhan
    Changqing Wu
    Pengyu Geng
    Xiaoyan Sun
    Yunsong Wu
    Shuijun Zhang
    Jianhua Qin
    Zhengping Zhuang
    Yang Liu
    Journal of Experimental & Clinical Cancer Research, 38
  • [47] EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
    Yin, Yalei
    Sun, Mingju
    Zhan, Xi
    Wu, Changqing
    Geng, Pengyu
    Sun, Xiaoyan
    Wu, Yunsong
    Zhang, Shuijun
    Qin, Jianhua
    Zhuang, Zhengping
    Liu, Yang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [48] TESC mediates resistance to lenvatinib in hepatocellular carcinoma by regulating cell autophagy
    Zhuang, Hao
    Zhang, Tingting
    Chen, Jiaqi
    CANCER RESEARCH, 2023, 84 (06)
  • [49] IDENTIFICATION OF microRNAs INVOLVED IN RESISTANCE OF LENVATINIB UNDER HYPOXIA IN HEPATOCELLULAR CARCINOMA
    Satoh, Mari
    Kogure, Takayuki
    Ito, Takehito
    Takahashi, Masanori
    Usui, Kensuke
    Okada, Kouji
    Satoh, Kennichi
    HEPATOLOGY, 2023, 78 : S1990 - S1991
  • [50] HDAC9 as a potential regulator of lenvatinib resistance in hepatocellular carcinoma
    Xie, Yunong
    Zhang, Minghe
    Liu, Yan
    Liu, Linglin
    Cheng, Alfred Sze-Lok
    Ma, Stephanie
    Tong, Man
    CANCER RESEARCH, 2023, 84 (06)